Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2011-04-05
2011-04-05
Bowman, Amy (Department: 1635)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C536S023100, C514S04400A, C435S320100, C435S325000
Reexamination Certificate
active
07919613
ABSTRACT:
The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a SCAP gene (Human SCAP gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of a SCAP gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by Human SCAP expression and the expression of a SCAP gene using the pharmaceutical composition; and methods for inhibiting the expression of a SCAP gene in a cell.
REFERENCES:
patent: 5801154 (1998-09-01), Baracchini et al.
patent: 6054299 (2000-04-01), Conrad
patent: 2003/0143732 (2003-07-01), Fosnaugh et al.
patent: 2003/0170891 (2003-09-01), McSwiggen
patent: 2005/0027103 (2005-02-01), Tang et al.
patent: 101 005865 (2002-04-01), None
patent: 1 560 931 (2005-08-01), None
patent: 2 213 738 (2010-08-01), None
patent: WO 99/53050 (1966-10-01), None
patent: WO 99/32619 (1999-01-01), None
patent: WO 99/61631 (1999-12-01), None
patent: WO 00/22113 (2000-04-01), None
patent: WO 00/22114 (2000-04-01), None
patent: WO 2004/045543 (2004-06-01), None
patent: WO 2005/014782 (2005-02-01), None
patent: WO 00/44895 (2010-08-01), None
Anderson et al., “From cholesterol homeostatasis to new paradigms in membrane biology,”Trends in Cell Biology, 12(10):534-539, 2003.
Briggs et al., “Nuclear protein that binds sterol regulatory element of low density lioprotein promotor,”The Journal of Biological Chemistry, 268(19):14490-14496, 1993.
Browning et al., “Molecular mediators of hepatic steatosis and livery injury,”The Journal of Clinical Investigation, 114(2):147-152, 2004.
Couture et al., “Anti-gene therapy: the use of ribozymes to inhibit gene function,”TIG, 12(12):510-515, 1996.
Elbashir et al., “Functional anatomy of siRNAs for mediating efficient RNAi inDrosophila melanogasterembryo lysate,”The Embo Journal, 20(23):6877-6888, 2001.
Engelking et al., “Overexpression of Insig-1 in the livers of transgenic mice inhibits SREBP processing and reduces insulin-stimulated lipogenesis,”The Journal of Clinical Investigation, 113(8):1168-1175, 2004.
GenBank Accession No. NM)012235.2, “Homo sapiens,” 1996.
GenBank Accession No. NM—01001144.1, “Mus musculus,” 2001.
GenBank Accession No. U67060, “Cricetus griseus,” 1996.
Glassmann et al., “Maintenance of an extrachromosomal plasmid vector in mouse embryonic stem cells,”Proc. Natl. Acad. Sci. USA, 92:1292-1296, 1995.
Hua et al., “SREBP-2, a second basic-helix-loop-helix-leucine zipper protein that stimulates transcription by binding to a sterol regulatory element,”Proc. Natl. Acad. Sci. USA, 90:11603-11607, 1993.
Hua et al., “Sterol resistance in CHO cells traced to point mutation in SREBP cleavage-activating protein,”Cell, 87:415-426, 1996.
humanRefSeq database, available from http://www.ncbi.nlm.nih.gov/refseq/, Rev. 17, May 5, 2006.
Mahato et al., “Modulation of gene expression by antisense and antigene oligodeoxynucleotides and small interfering RNA,”Expert Opinion on Drug Delivery, 2(1):3-28, 2005.
Matsuda, “SREBP cleavage-acting protein (SCAP) is required for increased lipid synthesis in liver induced by cholesterol deprivation and insulin elevation,”Genes and Development, 15:1206-1216, 2001.
Nohturfft et al., “Sterols regulate cycling of SREBP cleavage-activating protein (SCAP) between endoplasmic reticulum and golgi,”Proc. Natl. Acad. Sci., 96:11235-11240, 1999.
Office Communication, issued in U.S. Appl. No. 11/857,120, dated Jun. 4, 2009.
Office Communication, issued in U.S. Appl. No. 11/857,120, dated Mar. 24, 2009.
PCT International Preliminary Report on Patentability, issued in International application No. PCT/US2007/078740, mailed Apr. 2, 2009.
Rawson et al., “Comlementation cloning of S2P, a gene encoding a putative metalloprotease required for intramembrane cleavage of SREBPS,”Molecular Cell., 1:47-57, 1997.
Ryther, “siRNA therapeutics: Big potential from small RNAs,”Gene Therapy, 12:5-11, 2005.
Sakai et al., “Molecular identification of the sterol-regulated luminal protease that cleaves SREBPs and controls lipid composition of animal cells,”Molecular Cell, 2:505-514, 1998.
Scherer et al., “Approaches for the sequence-specific knockdown of mRNA,”Nat. Biotechnol., 21(12):1457-1465, 2003.
Shimomura et al., “Cholesterol feeding reduces nuclear forms of sterol regulatory element binding proteins in hamster liver,”Proc. Natl. Acad. Sci. USA, 94:12354-12359, 1997.
Yang et al., “Evidence that processed small dsRNAs may mediate sequence-specific mRNA degradation during RNAi inDrosophilaembryos,”Current Biology, 10(19):1191-1200, 2000.
Yokoyama et al., “SREBP-1, a basic-helix-loop-helix-leucine zipper protein that controls transcription of the low density lipoprotein receptor gene,”Cell, 75:187-197, 1993.
Database EMBL [Online] Aug. 18, 2010, “Sequence 812486 from Patent EP2213738,” retrieved from EBI accession No. EMBL:HD935770; Database accession No. HD935770.
Database EMBL [Online] Aug. 18, 2010, “Sequence 812544 from Patent EP2213738” retried from EBI accession No. EMBL:HD935828; Database accession No. HD935828.
Database EMBL [Online] Aug. 18, 2010, “Sequence 812550 from Patent EP2213738,” retrieved from EBI accession No. EMBL:HD935834; Database accession No. HD935834.
Database EMBL [Online] Aug. 18, 2010, “Sequence 858997 from Patent EP22I3738,” retrieved from EBI accession No. EMBL:HD982281; Database accession No. HD982281.
Database EMBL [Online] Aug. 18, 2010, “Sequence 859009 from Patent EP2213738,” retrieved from EBI accession No. EMBL:HD982293; database accession No. HD982293.
Database EMBL [Online] Aug. 27, 2010, “Sequence 1372884 from Patent EP2213738” retrieved from EBI accession No. EMBL:HH496169; Database accession No. HH496169.
Extended European Search Report, issued in European Patent Application No. 07842674.9, dated Jan. 24, 2011.
Zhou et al., “Vascular endothelial growth factor activation of sterol regulatory element binding protein—A potential role in angiogenesis,”Circulation Research, 95(5):471-478, 2004.
Brown Michael S.
Goldstein Joseph L.
Horton Jay D.
Moon Young-Ah
Soutschek Juergen
Alnylam Pharmaceuticals, Inc.
Board of Regents, the Unversity of Texas System
Bowman Amy
Fulbright & Jaworski L.L.P.
LandOfFree
RNAi modulation of SCAP and therapeutic uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with RNAi modulation of SCAP and therapeutic uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and RNAi modulation of SCAP and therapeutic uses thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2720335